Analysts Set Aspen Aerogels, Inc. (NYSE:ASPN) Target Price at $29.70

Aspen Aerogels, Inc. (NYSE:ASPN) has been assigned a consensus rating of “Buy” from the ten research firms that are covering the company, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $29.70.

A number of research analysts have recently commented on the company. Benchmark reaffirmed a “buy” rating and set a $14.00 target price on shares of Aspen Aerogels in a research note on Thursday, August 8th. Roth Mkm reiterated a “buy” rating and issued a $36.00 target price on shares of Aspen Aerogels in a research note on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Aspen Aerogels in a research note on Wednesday. TD Cowen upped their price target on shares of Aspen Aerogels from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, August 20th. Finally, B. Riley raised shares of Aspen Aerogels to a “strong-buy” rating in a research report on Tuesday, June 25th.

Aspen Aerogels Stock Down 3.8 %

NYSE ASPN opened at $21.60 on Friday. The stock has a 50 day moving average price of $26.00 and a 200-day moving average price of $24.35. Aspen Aerogels has a one year low of $6.62 and a one year high of $33.15. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.82 and a current ratio of 3.46. The company has a market capitalization of $1.64 billion, a P/E ratio of -49.08 and a beta of 2.16.

Aspen Aerogels (NYSE:ASPN) last issued its quarterly earnings data on Wednesday, August 7th. The construction company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.16. The company had revenue of $117.80 million for the quarter, compared to analysts’ expectations of $101.99 million. Aspen Aerogels had a return on equity of 0.74% and a net margin of 0.39%. The firm’s revenue for the quarter was up 144.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.22) earnings per share. As a group, equities analysts predict that Aspen Aerogels will post 0.21 EPS for the current fiscal year.

Insider Transactions at Aspen Aerogels

In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of Aspen Aerogels stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $30.03, for a total value of $1,902,550.65. Following the completion of the transaction, the chief executive officer now directly owns 483,640 shares of the company’s stock, valued at $14,523,709.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Donald R. Young sold 63,355 shares of the stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $30.03, for a total value of $1,902,550.65. Following the transaction, the chief executive officer now owns 483,640 shares in the company, valued at approximately $14,523,709.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Ricardo C. Rodriguez sold 32,465 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $30.14, for a total transaction of $978,495.10. Following the completion of the sale, the chief financial officer now directly owns 20,790 shares of the company’s stock, valued at approximately $626,610.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ASPN. GSA Capital Partners LLP acquired a new stake in shares of Aspen Aerogels in the 1st quarter worth approximately $1,181,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Aspen Aerogels in the first quarter valued at $388,000. Comerica Bank acquired a new position in Aspen Aerogels in the first quarter valued at $1,992,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Aspen Aerogels by 66.7% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 80,591 shares of the construction company’s stock worth $1,922,000 after buying an additional 32,243 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Aspen Aerogels by 5.1% in the 1st quarter. Vanguard Group Inc. now owns 3,619,702 shares of the construction company’s stock worth $63,707,000 after buying an additional 175,906 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.